Rsk inhibitors and therapeutic uses thereof
The present invention is directed to novel compounds and compositions that have Rsk specific inhibitory activity. In addition, inhibition of Rsk by the present compounds has been discovered to halt the proliferation of cancer cell lines while having little effect on the proliferation rate of normal cells. Therefore, the present invention identifies Rsk as a target for therapeutic intervention in diseased states in which the disease or the symptoms can be ameliorated by inhibition of Rsk catalytic activity.
1 - 12 . (canceled)
13 . A method of specifically inhibiting Rsk activity, said method comprising the step of contacting a Rsk enzyme with a compound represented by the general structure:
wherein R is H or OH, and R 1 , R 2 and R 3 are independently selected from the group consisting of hydroxy —OCOR 4 , —COR 4 and C 1 -C 4 alkoxy; and
R 4 is H or C 1 -C 4 alkyl.
14 . The method of claim 13 , wherein R is H or OH and R 1 , R 2 and R 3 are independently selected from the group consisting of hydroxy and —OCOCH 3 .
15 . The method of claims 13 or 14 wherein R is H.
16 . The method of claims 13 , 14 or 15 , wherein R 3 is —OCOCH 3 .
17 . A method of screening for Rsk inhibitory compounds, said method comprising the steps of
contacting a Rsk substrate with Rsk and a potential inhibitory compound under conditions that are permissive for kinase activity;
incubating the substrate for a predetermined length of time; and
determining if the substrate is phosphorylated, wherein a decrease in kinase activity relative to a reaction run in the absence of said potential inhibitory compound identifies an inhibitory compound.
18 . The method of claim 17 wherein the step of determining if the substrate is phosphorylated, comprises quantitating the level of phosphorylation through the use of phosphospecific antibodies.
19 - 47 . (canceled)